Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07103642 · ClinicalTrials.gov registry record
EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)
A clinical trial of Pulmonary Disease, Chronic Obstructive, sponsored by AstraZeneca.
- Completed
- Registry status
- 3,402
- Enrollment target
- 1
- Study location
NCT07103642 is a study of Pulmonary Disease, Chronic Obstructive that has completed, run by AstraZeneca. The registered enrollment target is 3,402 participants, above the 998-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (241% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07103642, a study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 3,402 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in Japan
Conditions Studied
Interventions
- DRUG BGF
Study Locations (1)
Delaware
- AstraZeneca - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,402 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2024-10-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07103642
The ClinicalTrials.gov registry entry for NCT07103642 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,402 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 998-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (241% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which BGF is the first listed.
NCT07103642 reports 1 study location spanning 1 distinct geographic area - top geographies include Delaware.
Frequently Asked Questions
What is clinical trial NCT07103642 about?
NCT07103642 is a clinical study titled "EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)". A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in Japan
What is the current status of trial NCT07103642?
This trial is currently completed. The enrollment target is 3,402 participants. The study started on 2024-08-15. Estimated completion is 2024-10-18.
What conditions does trial NCT07103642 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT07103642?
The interventions under investigation include: BGF (DRUG).
Who is sponsoring clinical trial NCT07103642?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07103642 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 1
-
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
RECRUITING · NA
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.